AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18721518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 7 drinks/week
Number of subjects: 5153
Study 18721518 — intervention group
Group type: EXPERIMENTAL
Intervention: >=8 drinks/week
Number of subjects: 5153
Study 15877983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 699
Study 15877983 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 699
Study 12182260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone and olopatadine
Number of subjects: 80
Study 12182260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone and fexofenadine
Number of subjects: 80
Study 12182260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10326791 — intervention group
Group type: EXPERIMENTAL
Intervention: fenretinide (4‐HPR) administered for a mean of 40 months
Number of subjects: 66
Study 10326791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fenretinide)
Number of subjects: 66
Study 7549449 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trabeculectomy
Number of subjects: 10
Study 7549449 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 10
Study 1952203 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air (or maintenance inspired oxygen fraction)
Number of subjects: 23
Study 1952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% O2
Number of subjects: 23
Study 7005681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil supplemented by phlebotomy
Number of subjects: 431
Study 7005681 — intervention group
Group type: COMPARATOR
Intervention: Radioactive phosphorus supplemented by phlebotomy
Number of subjects: 431
Study 7005681 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy alone
Number of subjects: 431
Study 31901794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Number of subjects: 150
Study 31901794 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 150
Study 31651042 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian Randomization (MR) using two-stage least squares (2SLS) procedure
Number of subjects: 0
Study 31651042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias-corrected estimator for the causal effect
Number of subjects: 0
Study 31651042 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric simulations
Number of subjects: 0
Study 28583814 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Roux-en-Y gastric bypass (RYGB)
Number of subjects: 166601
Study 28583814 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 166601
Study 28583814 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 166601
Study 28583814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 166601
Study 28583814 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion/duodenal switch (BPD/DS)
Number of subjects: 166601
Study 26337944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ranibizumab (1.0/0.1 ml or 2.0 mg/0.05 ml; n=15)
Number of subjects: 20
Study 26337944 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ranibizumab (0.5 mg/0.05 ml; n=5)
Number of subjects: 20
Study 23867026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 prevention and control messages
Number of subjects: 1992
Study 23867026 — intervention group
Group type: COMPARATOR
Intervention: Tobacco-cessation messages
Number of subjects: 1992
Study 21641183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 50
Study 21641183 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 50
Study 19176729 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 221
Study 19176729 — intervention group
Group type: COMPARATOR
Intervention: No maternal depressive symptoms (control group)
Number of subjects: 221
Study 19176729 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving practices
Number of subjects: 221
Study 17540216 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter/defibrillator (ICD)
Number of subjects: 2521
Study 17540216 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 2521
Study 17540216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2521
Study 17540216 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 2521
Study 17540216 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 2521
Study 15161453 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) training
Number of subjects: 89
Study 15161453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 89
Study 15161453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 11165993 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in combination with NSAID
Number of subjects: 0
Study 11165993 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone
Number of subjects: 0
Study 9432097 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (3 mg from MDI)
Number of subjects: 20
Study 9432097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8501471 — intervention group
Group type: EXPERIMENTAL
Intervention: First-class stamp
Number of subjects: 380
Study 8501471 — intervention group
Group type: COMPARATOR
Intervention: Business reply mail
Number of subjects: 380
Study 3690029 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate therapy
Number of subjects: 11
Study 3690029 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11
Study 31383515 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) through a Turbosonic vibratory machine for 10 minutes
Number of subjects: 44
Study 31383515 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized perilaryngeal vibration (LPV) with a Novofan vibrator for 10 minutes
Number of subjects: 44
Study 31383515 — intervention group
Group type: COMPARATOR
Intervention: Control (sham hand-held vibratory device)
Number of subjects: 44
Study 30834870 — intervention group
Group type: EXPERIMENTAL
Intervention: Contec CMS50D Fingertip Pulse Oximeter
Number of subjects: 220
Study 30834870 — intervention group
Group type: COMPARATOR
Intervention: Nihon Kohden Life Scope MU-631 RK conventional bedside monitor
Number of subjects: 220
Study 28364943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 78
Study 28364943 — intervention group
Group type: EXPERIMENTAL
Intervention: Amygdala lesions
Number of subjects: 78
Study 28364943 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 78
Study 26433802 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at SP-6 and LI-4 points
Number of subjects: 63
Study 26433802 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at SP-6 and LI-4 points
Number of subjects: 63
Study 23795326 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education (oral and written)
Number of subjects: 135
Study 23795326 — intervention group
Group type: COMPARATOR
Intervention: No preoperative patient education (control group)
Number of subjects: 135
Study 23795326 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education
Number of subjects: 135
Study 21225239 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan, 32 mg once daily
Number of subjects: 178
Study 21225239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 18996032 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Number of subjects: 15
Study 18996032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 15
Study 17943080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 339
Study 17943080 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 339
Study 15114554 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of asthmatic children
Number of subjects: 863
Study 15114554 — intervention group
Group type: COMPARATOR
Intervention: Health professionals (specialists)
Number of subjects: 863
Study 15114554 — intervention group
Group type: COMPARATOR
Intervention: Local clinicians
Number of subjects: 863
Study 15114554 — intervention group
Group type: COMPARATOR
Intervention: Parents (general)
Number of subjects: 863
Study 11817925 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences, self-efficacy, perceived benefits, and perceived barriers
Number of subjects: 2390
Study 11817925 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition as a perceived benefit
Number of subjects: 2390
Study 11817925 — intervention group
Group type: EXPERIMENTAL
Intervention: Health as a perceived benefit
Number of subjects: 2390
Study 11817925 — intervention group
Group type: EXPERIMENTAL
Intervention: Health concerns as perceived barriers
Number of subjects: 2390
Study 9849107 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial report trials
Number of subjects: 26
Study 9849107 — intervention group
Group type: COMPARATOR
Intervention: Whole report trials
Number of subjects: 26
Study 8190433 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor
Number of subjects: 7229
Study 8190433 — intervention group
Group type: COMPARATOR
Intervention: Elective repeat cesarean
Number of subjects: 7229
Study 2678885 — intervention group
Group type: EXPERIMENTAL
Intervention: Savlon as a cleansing agent before ocular surgery
Number of subjects: 0
Study 2678885 — intervention group
Group type: COMPARATOR
Intervention: Betadine as a safer antiseptic
Number of subjects: 0
Study 4855182 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' affective responses to patients or families
Number of subjects: 0
Study 4855182 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment prognosis ratings by therapists
Number of subjects: 0
Study 4855182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of psychopathology
Number of subjects: 0
Study 31078139 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BT)
Number of subjects: 94
Study 31078139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 94
Study 27811168 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 220
Study 27811168 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 220
Study 25858909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 µg twice daily
Number of subjects: 30
Study 25858909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25858909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 µg twice daily (excluding patients who changed prednisolone dose)
Number of subjects: 30
Study 22841906 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary biventricular pacing
Number of subjects: 50
Study 22841906 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no pacing)
Number of subjects: 50
Study 21145862 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling (intervention group)
Number of subjects: 355
Study 21145862 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (attention-control group)
Number of subjects: 355
Study 19695749 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical knee
Number of subjects: 18
Study 19695749 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-involved limb
Number of subjects: 18
Study 19695749 — intervention group
Group type: COMPARATOR
Intervention: Control limbs
Number of subjects: 18
Study 17258770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1484
Study 17258770 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1484
Study 15065933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-2 structure learning in young participants
Number of subjects: 48
Study 15065933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-2 structure learning in older participants
Number of subjects: 48
Study 15065933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-3 structure learning in young participants
Number of subjects: 48
Study 15065933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-3 structure learning in older participants
Number of subjects: 48
Study 11211366 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) - doses: placebo, low, middle, high
Number of subjects: 289
Study 11211366 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) - total daily dose limit of 35 mg for children weighing less than 25 kg
Number of subjects: 289
Study 9644316 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy (Arm B): CDDP (40 mg/m2), VDS (3 mg/m2), MMC (4 mg/m2) on day 1, followed by CDDP (20 mg/m2), VDS (1.5 mg/m2), MMC (2 mg/m2) weekly.
Number of subjects: 78
Study 9644316 — intervention group
Group type: COMPARATOR
Intervention: Monthly chemotherapy (Arm A): CDDP (80 mg/m2) monthly on day 1, VDS (3 mg/m2) on days 1 and 8, MMC (8 mg/m2) on day 1.
Number of subjects: 78
Study 7829187 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - opposite hip flexed beyond 90 degrees, abducted and externally rotated
Number of subjects: 100
Study 7829187 — intervention group
Group type: COMPARATOR
Intervention: Group I - opposite hip brought to full abduction, neutral flexion and neutral rotation
Number of subjects: 100
Study 2513239 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day sigmoidoscopy and double contrast barium enema
Number of subjects: 400
Study 2513239 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day sigmoidoscopy
Number of subjects: 400
Study 50948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 8
Study 50948 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 50948 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic torticollis patients
Number of subjects: 8
Study 50948 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogenic torticollis patients
Number of subjects: 8
Study 31564829 — intervention group
Group type: EXPERIMENTAL
Intervention: New generic formulation of S-1
Number of subjects: 29
Study 31564829 — intervention group
Group type: COMPARATOR
Intervention: Branded reference formulation of S-1
Number of subjects: 29
Study 28158239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Intervention (FVI)
Number of subjects: 171
Study 28158239 — intervention group
Group type: COMPARATOR
Intervention: Diet-as-usual control
Number of subjects: 171
Study 28158239 — intervention group
Group type: COMPARATOR
Intervention: Ecological Momentary Intervention (EMI)
Number of subjects: 171
Study 24955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating guidance and monitoring by parents
Number of subjects: 203
Study 24955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of parental control (child control)
Number of subjects: 203
Study 24955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of fussy eaters
Number of subjects: 203
Study 24955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fussy eaters
Number of subjects: 203
Study 24955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fussy eaters with food-restrictive parents
Number of subjects: 203
Study 22925226 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a maximum dose of 3000 mg
Number of subjects: 42
Study 22925226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 16945231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam administered
Number of subjects: 252
Study 16945231 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam administered
Number of subjects: 252
Study 16945231 — intervention group
Group type: COMPARATOR
Intervention: Placebo with saline administration
Number of subjects: 252
Study 12656544 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urine output
Number of subjects: 14
Study 12656544 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 14
Study 12656544 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured creatinine clearance (CrCl)
Number of subjects: 14
Study 12656544 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwartz equation for estimating CrCl
Number of subjects: 14
Study 12656544 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between measured CrCl and serum creatinine or urine production
Number of subjects: 14
Study 10356916 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic complex of amino acids (100 mg 3 times a day for 20 days)
Number of subjects: 90
Study 10356916 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study 8568118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate alone (56.25 mmol/L)
Number of subjects: 6
Study 8568118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate plus propionate (56.25 mmol/L + 18.75 mmol/L)
Number of subjects: 6
Study 8568118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate plus calcium (56.25 mmol/L + 50 mmol/L)
Number of subjects: 6
Study 8568118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate, propionate, and calcium together (56.25 mmol/L + 18.75 mmol/L + 50 mmol/L)
Number of subjects: 6
Study 8568118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionate alone (18.75 mmol/L)
Number of subjects: 6
Study 1836088 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol 5-10 mg
Number of subjects: 87
Study 1836088 — intervention group
Group type: COMPARATOR
Intervention: DMPA (intramuscular administration)
Number of subjects: 87
Study 7058319 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (3 X 200 mg daily)
Number of subjects: 66
Study 7058319 — intervention group
Group type: EXPERIMENTAL
Intervention: colestipol (2 X 10 g per day)
Number of subjects: 66
Study 7058319 — intervention group
Group type: EXPERIMENTAL
Intervention: probucol (2 X 500 mg daily)
Number of subjects: 66
Study 7058319 — intervention group
Group type: COMPARATOR
Intervention: dietary treatment alone
Number of subjects: 66
Study 7058319 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 31412278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group
Number of subjects: 0
Study 31412278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27276431 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 25 mg ARA/100 kcal
Number of subjects: 89
Study 27276431 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 34 mg ARA/100 kcal
Number of subjects: 89
Study 27276431 — intervention group
Group type: COMPARATOR
Intervention: Formula containing 0 mg ARA/100 kcal
Number of subjects: 89
Study 26691663 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mindfulness training course
Number of subjects: 30
Study 23765601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (ulinastatin group - UG)
Number of subjects: 40
Study 23765601 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 21517195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude voucher condition
Number of subjects: 36
Study 21517195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-magnitude voucher condition
Number of subjects: 36
Study 21517195 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 36
Study 21517195 — intervention group
Group type: COMPARATOR
Intervention: Interaction between DD and treatment condition
Number of subjects: 36
Study 18359421 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretest probability
Number of subjects: 740
Study 18359421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pretest probability
Number of subjects: 740
Study 18359421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretest probability
Number of subjects: 740
Study 18359421 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CPIS
Number of subjects: 740
Study 16867025 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem modified-release (MR) 12.5 mg
Number of subjects: 24
Study 16867025 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem immediate-release (IR) 10 mg
Number of subjects: 24
Study 16867025 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem intravenous (i.v.) infusion 8 mg
Number of subjects: 24
Study 14564336 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle valve
Number of subjects: 39
Study 14564336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic valve
Number of subjects: 39
Study 14564336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracor valve
Number of subjects: 39
Study 14564336 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS valve
Number of subjects: 39
Study 10847261 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP materials
Number of subjects: 3627
Study 10847261 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP materials and outbound telephone call
Number of subjects: 3627
Study 10847261 — intervention group
Group type: COMPARATOR
Intervention: User's guide and audiotape (UG group)
Number of subjects: 3627
Study 9015779 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen extract (active product)
Number of subjects: 40
Study 9015779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1354275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (1 g per day) plus heparin (10,000 U per day) during and after surgery for 7 days
Number of subjects: 398
Study 1354275 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 398
Study 1354275 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 398
Study 6352304 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta-2-agonists (2.5 mg terbutaline)
Number of subjects: 10